Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $37.43

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have received an average rating of “Buy” from the seven analysts that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $37.43.

A number of research firms recently issued reports on DYN. Stifel Nicolaus upped their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Piper Sandler increased their target price on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Chardan Capital increased their target price on shares of Dyne Therapeutics from $20.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, March 8th. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of Dyne Therapeutics in a report on Wednesday, March 6th. Finally, Raymond James raised their price target on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the company a “strong-buy” rating in a report on Thursday, January 4th.

Dyne Therapeutics Trading Up 4.4 %

Shares of NASDAQ DYN opened at $24.73 on Wednesday. The firm has a 50 day moving average of $26.07 and a 200 day moving average of $17.70. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -6.28 and a beta of 0.95. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $30.27.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). Sell-side analysts predict that Dyne Therapeutics will post -3.25 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Wildon Farwell sold 5,493 shares of Dyne Therapeutics stock in a transaction on Monday, February 12th. The shares were sold at an average price of $25.07, for a total transaction of $137,709.51. Following the sale, the insider now owns 163,503 shares of the company’s stock, valued at approximately $4,099,020.21. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Wildon Farwell sold 5,493 shares of Dyne Therapeutics stock in a transaction on Monday, February 12th. The stock was sold at an average price of $25.07, for a total transaction of $137,709.51. Following the transaction, the insider now owns 163,503 shares in the company, valued at approximately $4,099,020.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Richard William Scalzo sold 2,672 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $25.28, for a total transaction of $67,548.16. Following the completion of the sale, the senior vice president now owns 119,283 shares in the company, valued at $3,015,474.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,875,432 shares of company stock valued at $44,368,530. 20.77% of the stock is owned by company insiders.

Institutional Trading of Dyne Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DYN. Wetzel Investment Advisors Inc. acquired a new position in Dyne Therapeutics in the first quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. grew its holdings in Dyne Therapeutics by 355.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after purchasing an additional 5,541 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Dyne Therapeutics by 58.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock valued at $75,000 after purchasing an additional 3,092 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Dyne Therapeutics by 95.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock valued at $83,000 after purchasing an additional 4,552 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Dyne Therapeutics during the fourth quarter valued at $172,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.